Mr Adam Levysohn | Head of Global Market Access Biogen Biosimilars Business Unit
Biogen

Adam joined the biosimilars team in June 2015. He brings 13 years of market access experience, primarily from his time with Novo Nordisk in global, regional and affiliate roles including head of global market access and market access Europe. Prior to Novo Nordisk, Adam was responsible for Ilaris (canakinumab) access at Novartis where he worked closely with affiliates to understand contracting opportunities. In his latest role he was the head of global market access for CardioMetabolic at Takeda Pharmaceuticals.